Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'

MT Newswires Live

17小时前

Design Therapeutics (DSGN) said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.

The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.

The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.

The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.

Shares of the company were down 3.3% in recent trading.

Price: 4.70, Change: -0.16, Percent Change: -3.29

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2532888223"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532888223\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2532888223?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 00:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532888223","market":"sg","top_or_hot":-1,"title":"Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'","media":"MT Newswires Live","content":"<html><body><p> Design <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DSGN) said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.</p><p>The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.</p><p>The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.</p><p>The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.</p><p>Shares of the company were down 3.3% in recent trading.</p><p>Price: 4.70, Change: -0.16, Percent Change: -3.29</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDesign Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-02 00:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Design <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DSGN) said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.</p><p>The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.</p><p>The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.</p><p>The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.</p><p>Shares of the company were down 3.3% in recent trading.</p><p>Price: 4.70, Change: -0.16, Percent Change: -3.29</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DSGN","symbol_name":"Design Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2532888223","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532888223","pubTimestamp":1746116981,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Design Therapeutics  said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.Shares of the company were down 3.3% in recent trading.Price: 4.70, Change: -0.16, Percent Change: -3.29","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DSGN":"Design Therapeutics, Inc.","LENZ":"Therapeutics","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4539":"次新股","BK4007":"制药"},"translate_title":"Design Therapeutics表示治疗富克斯内皮角膜营养不良的滴眼液“耐受性良好”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DSGN":1,"LENZ":1},"content_text":"Design Therapeutics (DSGN) said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.Shares of the company were down 3.3% in recent trading.Price: 4.70, Change: -0.16, Percent Change: -3.29","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}